drugset / Trial / NCT04115514

Treatment of ARDS With Instilled T3

NCT04115514

Phase 2 Active not recruiting 68 enrolled University of Minnesota
RandomizedParallel-groupOpen-labelTreatment

Summary

It is hypothesized that instillation of Liothyronine Sodium (T3) into the airspace will be safe, well tolerated, and will increase alveolar fluid clearance and decrease inflammation in patients with ARDS, reflected in improved oxygenation index (OI) and oxygenation saturation index (OSI).

Timeline

Start
2020-03-30
Primary completion
2026-10-31
Completion
2026-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Liothyronine Small molecule 50 ug Other